董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Thomas H. Adams | 男 | Chief Executive Officer and Chairman of the Board, Director | 77 | 130.46万美元 | 未持股 | 2020-03-04 |
| John P. Brancaccio | 男 | Director | 71 | 16.00万美元 | 未持股 | 2020-03-04 |
| Gary S. Jacob | 男 | Director | 72 | 14.00万美元 | 未持股 | 2020-03-04 |
| Rodney S. Markin | 男 | Director | 63 | 16.00万美元 | 未持股 | 2020-03-04 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Thomas H. Adams | 男 | Chief Executive Officer and Chairman of the Board, Director | 77 | 130.46万美元 | 未持股 | 2020-03-04 |
| Mark Erlander | 男 | Chief Scientific Officer | 64 | 102.17万美元 | 未持股 | 2020-03-04 |
董事简历
中英对照 | 中文 | 英文- Thomas H. Adams
-
Thomas H. Adams自2009年4月起担任董事会主席，自2018年6月起担任我们的首席执行官。他目前是Hepion Pharmaceuticals，Inc。的董事，自2014年以来一直担任该职位。此前，Adams博士曾担任董事长。于2013年至2019年担任成像解决方案公司Clearbridge BioPhotonics，Inc。的职位，并于2009年至2019年担任Synergy Pharmaceuticals，Inc。的总监。他曾在IRIS International担任过多个领导职务，包括董事，个性化医学主管和首席技术官。从2005年到2012年被Danaher Corporation收购该公司的官员。从1998年到2006年，Adams博士是Leucadia Technologies的董事长兼首席执行官，该公司是一家私有生物技术公司，于2006年被IRIS International，Inc。收购。 Adams于1989年创立了Genta，Inc.，并担任首席执行官直到1997年。他还于1984年成立了Gen-Probe，Inc.，并担任了董事长兼首席执行官。 1989年被Chugai Biopharmaceuticals，Inc。收购。Adams博士拥有博士学位。加州大学里弗赛德分校生物化学专业。
Thomas H. Adams has served as Chairman of the Board since April 2009 and as our Chief Executive Officer since June 2018. He is currently a Director at Hepion Pharmaceuticals, Inc. where he has served since 2014. Previously, Dr. Adams served as Chairman of Clearbridge BioPhotonics, Inc., an imaging solutions company, from 2013 to 2019 and as Director of Synergy Pharmaceuticals, Inc. from 2009 to 2019. He served in several leadership roles at IRIS International, including Director, Head of Personalized Medicine and Chief Technology Officer, from 2005 until the company's acquisition by Danaher Corporation in 2012. From 1998 to 2006 Dr. Adams was Chairman and Chief Executive Officer of Leucadia Technologies, a privately held biotechnology company which was acquired by IRIS International, Inc. in 2006. Dr. Adams founded Genta, Inc. in 1989 and served as its Chief Executive Officer until 1997. He also founded Gen-Probe, Inc. in 1984 and served as Chairman and Chief Executive Officer until its acquisition by Chugai Biopharmaceuticals, Inc. in 1989. Dr. Adams holds a Ph.D. in Biochemistry from the University of California, Riverside. - Thomas H. Adams自2009年4月起担任董事会主席，自2018年6月起担任我们的首席执行官。他目前是Hepion Pharmaceuticals，Inc。的董事，自2014年以来一直担任该职位。此前，Adams博士曾担任董事长。于2013年至2019年担任成像解决方案公司Clearbridge BioPhotonics，Inc。的职位，并于2009年至2019年担任Synergy Pharmaceuticals，Inc。的总监。他曾在IRIS International担任过多个领导职务，包括董事，个性化医学主管和首席技术官。从2005年到2012年被Danaher Corporation收购该公司的官员。从1998年到2006年，Adams博士是Leucadia Technologies的董事长兼首席执行官，该公司是一家私有生物技术公司，于2006年被IRIS International，Inc。收购。 Adams于1989年创立了Genta，Inc.，并担任首席执行官直到1997年。他还于1984年成立了Gen-Probe，Inc.，并担任了董事长兼首席执行官。 1989年被Chugai Biopharmaceuticals，Inc。收购。Adams博士拥有博士学位。加州大学里弗赛德分校生物化学专业。
- Thomas H. Adams has served as Chairman of the Board since April 2009 and as our Chief Executive Officer since June 2018. He is currently a Director at Hepion Pharmaceuticals, Inc. where he has served since 2014. Previously, Dr. Adams served as Chairman of Clearbridge BioPhotonics, Inc., an imaging solutions company, from 2013 to 2019 and as Director of Synergy Pharmaceuticals, Inc. from 2009 to 2019. He served in several leadership roles at IRIS International, including Director, Head of Personalized Medicine and Chief Technology Officer, from 2005 until the company's acquisition by Danaher Corporation in 2012. From 1998 to 2006 Dr. Adams was Chairman and Chief Executive Officer of Leucadia Technologies, a privately held biotechnology company which was acquired by IRIS International, Inc. in 2006. Dr. Adams founded Genta, Inc. in 1989 and served as its Chief Executive Officer until 1997. He also founded Gen-Probe, Inc. in 1984 and served as Chairman and Chief Executive Officer until its acquisition by Chugai Biopharmaceuticals, Inc. in 1989. Dr. Adams holds a Ph.D. in Biochemistry from the University of California, Riverside.
- John P. Brancaccio
-
John P. Brancaccio，已退休的注册会计师；2005年12月起，担任本公司董事。他从2004年4月起，担任Accelerated Technologies的首席财务官，这是医疗器械公司的孵化器。他目前是Tamir Biotechnology（原Alfacell Corporation）、Synergy Pharmaceuticals、ContraVir Pharmaceuticals（Synergy的子公司）的董事。
John P. Brancaccio a retired CPA, has served as a director of our Company since May 15 2013. Mr. Brancaccio was the Chief Financial Officer of Accelerated Technologies, Inc., an incubator for medical device companies from April 2004 until May 2017. Mr. Brancaccio served as a director for Callisto Pharmaceuticals, Inc. from April 2004 until its merger with Synergy Pharmaceuticals, Inc. in January 2013 and was formerly a director of Tamir Biotechnology, Inc. formerly Alfacell Corporation since April 2004 until May 2020. He is also a director of Cardiff Oncology, Inc. since December 2005 Rasna Therapeutics, Inc. since September 2016 OKYO Pharma Limited since June 2020 and Tiziana Life Sciences plc since July 2020. Mr. Brancaccio served as a director of Synergy from July 2008 until April 2019. - John P. Brancaccio，已退休的注册会计师；2005年12月起，担任本公司董事。他从2004年4月起，担任Accelerated Technologies的首席财务官，这是医疗器械公司的孵化器。他目前是Tamir Biotechnology（原Alfacell Corporation）、Synergy Pharmaceuticals、ContraVir Pharmaceuticals（Synergy的子公司）的董事。
- John P. Brancaccio a retired CPA, has served as a director of our Company since May 15 2013. Mr. Brancaccio was the Chief Financial Officer of Accelerated Technologies, Inc., an incubator for medical device companies from April 2004 until May 2017. Mr. Brancaccio served as a director for Callisto Pharmaceuticals, Inc. from April 2004 until its merger with Synergy Pharmaceuticals, Inc. in January 2013 and was formerly a director of Tamir Biotechnology, Inc. formerly Alfacell Corporation since April 2004 until May 2020. He is also a director of Cardiff Oncology, Inc. since December 2005 Rasna Therapeutics, Inc. since September 2016 OKYO Pharma Limited since June 2020 and Tiziana Life Sciences plc since July 2020. Mr. Brancaccio served as a director of Synergy from July 2008 until April 2019.
- Gary S. Jacob
-
Gary S. Jacob。 Gary S. Jacob博士自2009年2月起担任公司董事。自2008年7月以来，Jacob博士一直担任Synergy Pharmaceuticals Inc.的总裁，首席执行官和董事，并担任该公司的董事。 主席自2013年9月起。雅各布博士自2013年5月起担任ContraVir Pharmaceuticals，Inc.的董事长。雅各博士于2004年10月起担任Callisto Pharmaceuticals，Inc.的董事，直至2013年1月与Synergy Pharmaceuticals，Inc.合并。 1999年之前，Jacob博士担任孟山都科学研究员，专攻糖生物学领域，1997年至1998年，他担任孟山都公司的功能基因组学，企业科学与技术总监。 雅各博士获得了B.S。 在密苏里大学化学，并拥有博士学位。 来自威斯康星大学麦迪逊分校的生物化学专业。
Gary S. Jacob,has served as Chief Executive Officer and a director of Okyo Pharma Limited since January 2021. From November 2018 to March 2020, Dr. Jacob was the Chief Executive Officer of Immuron Limited, an Australian microbiome biopharmaceutical company. From July 2008 until December 2017, Dr. Jacob was President and Chief Executive Officer of Synergy Pharmaceuticals Inc., a biopharmaceutical company, where he held various positions from July 2008 to November 2018 and he served as its Chairman from September 2013 to November 2018. On December 12, 2018, Synergy Pharmaceuticals Inc. filed a petition for relief under Chapter 11 of the U.S. Bankruptcy Code. Since March 19, 2014, Dr. Jacob has been Chairman of the Board of Hepion Pharmaceuticals, Inc., a biotechnology company, and earlier served as its Chief Executive Officer from May 15, 2013 until March 19, 2014. Dr. Jacob served as Chief Executive Officer of Callisto Pharmaceuticals, Inc. from May 2003 until January 2013 and a director from October 2004 until January 2013. Dr. Jacob also serves as a director of Rasna Therapeutics, Inc., and is a past director of Cardiff Oncology, Inc. Dr. Jacob has over 35 years of experience in the pharmaceutical and biotechnology industries across multiple disciplines including research & development, operations and business development. Prior to 1999, Dr. Jacob served as a Monsanto Science Fellow, specializing in the field of glycobiology, and from 1997 to 1998 Dr. Jacob was Director of Functional Genomics, Corporate Science & Technology, at Monsanto Company. Dr. Jacob also served from 1990 to 1997 as Director of Glycobiology at G.D. Searle Pharmaceuticals Inc. During the period of 1986 to 1990, he was Manager of the G.D. Searle Glycobiology Group at Oxford University, England. - Gary S. Jacob。 Gary S. Jacob博士自2009年2月起担任公司董事。自2008年7月以来，Jacob博士一直担任Synergy Pharmaceuticals Inc.的总裁，首席执行官和董事，并担任该公司的董事。 主席自2013年9月起。雅各布博士自2013年5月起担任ContraVir Pharmaceuticals，Inc.的董事长。雅各博士于2004年10月起担任Callisto Pharmaceuticals，Inc.的董事，直至2013年1月与Synergy Pharmaceuticals，Inc.合并。 1999年之前，Jacob博士担任孟山都科学研究员，专攻糖生物学领域，1997年至1998年，他担任孟山都公司的功能基因组学，企业科学与技术总监。 雅各博士获得了B.S。 在密苏里大学化学，并拥有博士学位。 来自威斯康星大学麦迪逊分校的生物化学专业。
- Gary S. Jacob,has served as Chief Executive Officer and a director of Okyo Pharma Limited since January 2021. From November 2018 to March 2020, Dr. Jacob was the Chief Executive Officer of Immuron Limited, an Australian microbiome biopharmaceutical company. From July 2008 until December 2017, Dr. Jacob was President and Chief Executive Officer of Synergy Pharmaceuticals Inc., a biopharmaceutical company, where he held various positions from July 2008 to November 2018 and he served as its Chairman from September 2013 to November 2018. On December 12, 2018, Synergy Pharmaceuticals Inc. filed a petition for relief under Chapter 11 of the U.S. Bankruptcy Code. Since March 19, 2014, Dr. Jacob has been Chairman of the Board of Hepion Pharmaceuticals, Inc., a biotechnology company, and earlier served as its Chief Executive Officer from May 15, 2013 until March 19, 2014. Dr. Jacob served as Chief Executive Officer of Callisto Pharmaceuticals, Inc. from May 2003 until January 2013 and a director from October 2004 until January 2013. Dr. Jacob also serves as a director of Rasna Therapeutics, Inc., and is a past director of Cardiff Oncology, Inc. Dr. Jacob has over 35 years of experience in the pharmaceutical and biotechnology industries across multiple disciplines including research & development, operations and business development. Prior to 1999, Dr. Jacob served as a Monsanto Science Fellow, specializing in the field of glycobiology, and from 1997 to 1998 Dr. Jacob was Director of Functional Genomics, Corporate Science & Technology, at Monsanto Company. Dr. Jacob also served from 1990 to 1997 as Director of Glycobiology at G.D. Searle Pharmaceuticals Inc. During the period of 1986 to 1990, he was Manager of the G.D. Searle Glycobiology Group at Oxford University, England.
- Rodney S. Markin
-
Rodney S. Markin。 Rodney S. Markin，医学博士，博士，自2014年2月起担任本公司董事。Markin博士自2017年8月起担任内布拉斯加大学的首席运营官。Markin博士曾担任首席技术官兼 2017年至2017年7月，内布拉斯加大学医学中心商业发展副校长； 自1985年以来担任病理学和微生物学教授； 自2005年起担任David T. Purtilo杰出教授病理学和微生物学； 自1990年起担任外科学院礼貌教授，自2013年起担任精神病学礼貌教授。Markin博士还是儿童医院和医疗中心基金会董事会主席，Keck研究所董事会成员，董事会成员。 -A-Wish基金会和自2015年7月起在PerceptiMed董事会任职。Markin博士于2007年3月至2014年12月在Transgenomic，Inc。董事会任职。
Rodney S. Markin has been a Director since February 2014. He is currently Vice President for Network Development, Nebraska Medicine and Associate Vice Chancellor for Business and Executive Director of the UNeTech Institute at the University of Nebraska Medical Center, a public center of health sciences research, patient care, and education, where he has served since July 1985. Dr. Markin also serves concurrently as Courtesy Professor of Psychiatry and Courtesy Professor of Surgery at the University of Nebraska and David T. Purtilo Distinguished Professor of Pathology and Microbiology since 2005 and Professor of Pathology and Microbiology. He serves on the boards of Perceptimed Inc. since 2014 MikroScan Technologies Inc. since 2015 Afaxys Inc. since 2017 and Paradigm Diagnostics Inc. since 2018. In the non-profit sector, Dr. Markin serves as a Director of Children's Hospital and Medical Center Foundation and as Trustee for Keck Graduate Institute, and the Make-A-Wish Foundation, since 2015. Previously, Dr. Markin served as Chief Technology Officer and Associate Vice Chancellor for Business Development at the University of Nebraska from 2011 to 2017 and as Director of Transgenomic, Inc. from 2007 to 2014. - Rodney S. Markin。 Rodney S. Markin，医学博士，博士，自2014年2月起担任本公司董事。Markin博士自2017年8月起担任内布拉斯加大学的首席运营官。Markin博士曾担任首席技术官兼 2017年至2017年7月，内布拉斯加大学医学中心商业发展副校长； 自1985年以来担任病理学和微生物学教授； 自2005年起担任David T. Purtilo杰出教授病理学和微生物学； 自1990年起担任外科学院礼貌教授，自2013年起担任精神病学礼貌教授。Markin博士还是儿童医院和医疗中心基金会董事会主席，Keck研究所董事会成员，董事会成员。 -A-Wish基金会和自2015年7月起在PerceptiMed董事会任职。Markin博士于2007年3月至2014年12月在Transgenomic，Inc。董事会任职。
- Rodney S. Markin has been a Director since February 2014. He is currently Vice President for Network Development, Nebraska Medicine and Associate Vice Chancellor for Business and Executive Director of the UNeTech Institute at the University of Nebraska Medical Center, a public center of health sciences research, patient care, and education, where he has served since July 1985. Dr. Markin also serves concurrently as Courtesy Professor of Psychiatry and Courtesy Professor of Surgery at the University of Nebraska and David T. Purtilo Distinguished Professor of Pathology and Microbiology since 2005 and Professor of Pathology and Microbiology. He serves on the boards of Perceptimed Inc. since 2014 MikroScan Technologies Inc. since 2015 Afaxys Inc. since 2017 and Paradigm Diagnostics Inc. since 2018. In the non-profit sector, Dr. Markin serves as a Director of Children's Hospital and Medical Center Foundation and as Trustee for Keck Graduate Institute, and the Make-A-Wish Foundation, since 2015. Previously, Dr. Markin served as Chief Technology Officer and Associate Vice Chancellor for Business Development at the University of Nebraska from 2011 to 2017 and as Director of Transgenomic, Inc. from 2007 to 2014.
高管简历
中英对照 | 中文 | 英文- Thomas H. Adams
Thomas H. Adams自2009年4月起担任董事会主席，自2018年6月起担任我们的首席执行官。他目前是Hepion Pharmaceuticals，Inc。的董事，自2014年以来一直担任该职位。此前，Adams博士曾担任董事长。于2013年至2019年担任成像解决方案公司Clearbridge BioPhotonics，Inc。的职位，并于2009年至2019年担任Synergy Pharmaceuticals，Inc。的总监。他曾在IRIS International担任过多个领导职务，包括董事，个性化医学主管和首席技术官。从2005年到2012年被Danaher Corporation收购该公司的官员。从1998年到2006年，Adams博士是Leucadia Technologies的董事长兼首席执行官，该公司是一家私有生物技术公司，于2006年被IRIS International，Inc。收购。 Adams于1989年创立了Genta，Inc.，并担任首席执行官直到1997年。他还于1984年成立了Gen-Probe，Inc.，并担任了董事长兼首席执行官。 1989年被Chugai Biopharmaceuticals，Inc。收购。Adams博士拥有博士学位。加州大学里弗赛德分校生物化学专业。
Thomas H. Adams has served as Chairman of the Board since April 2009 and as our Chief Executive Officer since June 2018. He is currently a Director at Hepion Pharmaceuticals, Inc. where he has served since 2014. Previously, Dr. Adams served as Chairman of Clearbridge BioPhotonics, Inc., an imaging solutions company, from 2013 to 2019 and as Director of Synergy Pharmaceuticals, Inc. from 2009 to 2019. He served in several leadership roles at IRIS International, including Director, Head of Personalized Medicine and Chief Technology Officer, from 2005 until the company's acquisition by Danaher Corporation in 2012. From 1998 to 2006 Dr. Adams was Chairman and Chief Executive Officer of Leucadia Technologies, a privately held biotechnology company which was acquired by IRIS International, Inc. in 2006. Dr. Adams founded Genta, Inc. in 1989 and served as its Chief Executive Officer until 1997. He also founded Gen-Probe, Inc. in 1984 and served as Chairman and Chief Executive Officer until its acquisition by Chugai Biopharmaceuticals, Inc. in 1989. Dr. Adams holds a Ph.D. in Biochemistry from the University of California, Riverside.- Thomas H. Adams自2009年4月起担任董事会主席，自2018年6月起担任我们的首席执行官。他目前是Hepion Pharmaceuticals，Inc。的董事，自2014年以来一直担任该职位。此前，Adams博士曾担任董事长。于2013年至2019年担任成像解决方案公司Clearbridge BioPhotonics，Inc。的职位，并于2009年至2019年担任Synergy Pharmaceuticals，Inc。的总监。他曾在IRIS International担任过多个领导职务，包括董事，个性化医学主管和首席技术官。从2005年到2012年被Danaher Corporation收购该公司的官员。从1998年到2006年，Adams博士是Leucadia Technologies的董事长兼首席执行官，该公司是一家私有生物技术公司，于2006年被IRIS International，Inc。收购。 Adams于1989年创立了Genta，Inc.，并担任首席执行官直到1997年。他还于1984年成立了Gen-Probe，Inc.，并担任了董事长兼首席执行官。 1989年被Chugai Biopharmaceuticals，Inc。收购。Adams博士拥有博士学位。加州大学里弗赛德分校生物化学专业。
- Thomas H. Adams has served as Chairman of the Board since April 2009 and as our Chief Executive Officer since June 2018. He is currently a Director at Hepion Pharmaceuticals, Inc. where he has served since 2014. Previously, Dr. Adams served as Chairman of Clearbridge BioPhotonics, Inc., an imaging solutions company, from 2013 to 2019 and as Director of Synergy Pharmaceuticals, Inc. from 2009 to 2019. He served in several leadership roles at IRIS International, including Director, Head of Personalized Medicine and Chief Technology Officer, from 2005 until the company's acquisition by Danaher Corporation in 2012. From 1998 to 2006 Dr. Adams was Chairman and Chief Executive Officer of Leucadia Technologies, a privately held biotechnology company which was acquired by IRIS International, Inc. in 2006. Dr. Adams founded Genta, Inc. in 1989 and served as its Chief Executive Officer until 1997. He also founded Gen-Probe, Inc. in 1984 and served as Chairman and Chief Executive Officer until its acquisition by Chugai Biopharmaceuticals, Inc. in 1989. Dr. Adams holds a Ph.D. in Biochemistry from the University of California, Riverside.
- Mark Erlander
Mark Erlander自2013年3月以来一直担任我们的首席科学官。担任现任职务之前，他曾担任BioTheranostics公司（BioM&233；Rieux公司（分子诊断测试公司，专注于肿瘤临床应用）的子公司）的首席科学官（从2008年到2013年）。Erlander从2000年到2008年担任Arcturus，Inc.（后为Aviaradx，2008年被Biom&233；Rieux收购）首席科学官。Erlander博士从1994年到2000年进入Therapeutics担任组长，然后在强生公司担任药物发现研究员。从1991年到1994年，Erlander博士是Scripps Research的博士后，然后是助理教授。他拥有44项已发布专利、50多项待审申请，并共同撰写了90多篇科学出版物。Erlander博士拥有加州大学戴维斯分校（University of California，Davis）的生物化学学士学位，爱荷华州立大学（Iowa State University）的生物化学硕士学位，以及加州大学洛杉矶分校（University of California，Los Angeles）的神经科学博士学位。
Mark Erlander has served as our Chief Scientific Officer since March 2013. Prior to his current assignment, he was Chief Scientific Officer at bioTheranostics, a subsidiary of bioMérieux, a molecular diagnostic testing company focused on clinical applications in oncology, where he served from 2008 to 2013. From 2000 to 2008 Dr. Erlander was Chief Scientific Officer at Arcturus, Inc. later AviaraDx, which was acquired by bioMérieux in 2008. Dr. Erlander entered therapeutics as a Group Leader and then Research Fellow in drug discovery at Johnson & Johnson from 1994 to 2000. From 1991 to 1994 Dr. Erlander was a Postdoctoral Fellow and then Assistant Professor at Scripps Research. He has 44 issued patents, over 50 pending applications, and has co-authored over 90 scientific publications. Dr. Erlander holds a B.S. in Biochemistry from the University of California, Davis, an M.S. degree in Biochemistry from Iowa State University, and a Ph.D. in Neuroscience from the University of California, Los Angeles.- Mark Erlander自2013年3月以来一直担任我们的首席科学官。担任现任职务之前，他曾担任BioTheranostics公司（BioM&233；Rieux公司（分子诊断测试公司，专注于肿瘤临床应用）的子公司）的首席科学官（从2008年到2013年）。Erlander从2000年到2008年担任Arcturus，Inc.（后为Aviaradx，2008年被Biom&233；Rieux收购）首席科学官。Erlander博士从1994年到2000年进入Therapeutics担任组长，然后在强生公司担任药物发现研究员。从1991年到1994年，Erlander博士是Scripps Research的博士后，然后是助理教授。他拥有44项已发布专利、50多项待审申请，并共同撰写了90多篇科学出版物。Erlander博士拥有加州大学戴维斯分校（University of California，Davis）的生物化学学士学位，爱荷华州立大学（Iowa State University）的生物化学硕士学位，以及加州大学洛杉矶分校（University of California，Los Angeles）的神经科学博士学位。
- Mark Erlander has served as our Chief Scientific Officer since March 2013. Prior to his current assignment, he was Chief Scientific Officer at bioTheranostics, a subsidiary of bioMérieux, a molecular diagnostic testing company focused on clinical applications in oncology, where he served from 2008 to 2013. From 2000 to 2008 Dr. Erlander was Chief Scientific Officer at Arcturus, Inc. later AviaraDx, which was acquired by bioMérieux in 2008. Dr. Erlander entered therapeutics as a Group Leader and then Research Fellow in drug discovery at Johnson & Johnson from 1994 to 2000. From 1991 to 1994 Dr. Erlander was a Postdoctoral Fellow and then Assistant Professor at Scripps Research. He has 44 issued patents, over 50 pending applications, and has co-authored over 90 scientific publications. Dr. Erlander holds a B.S. in Biochemistry from the University of California, Davis, an M.S. degree in Biochemistry from Iowa State University, and a Ph.D. in Neuroscience from the University of California, Los Angeles.